Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including multiple sclerosis, Parkinson’s disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
04/28/16 8-K Current report filing
04/25/16 SC 13D Statement of Beneficial Ownership
04/21/16 4 Statement of Changes in Beneficial Ownership
04/20/16 SC TO-T/A Amended tender offer statement by Third Party

Stock Quote

ACOR (Common Stock) $ 27.34 -1.57 (-5.43%) Volume: 571,336 MORE April 28, 2016

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.